Last 8.35 INR
Change Today -0.25 / -2.91%
Volume 25.4K
PDL On Other Exchanges
Symbol
Exchange
Natl India
As of 6:06 AM 03/5/15 All times are local (Market data is delayed by at least 15 minutes).

parabolic drugs ltd (PDL) Snapshot

Open
8.60
Previous Close
8.60
Day High
8.70
Day Low
8.35
52 Week High
09/16/14 - 18.20
52 Week Low
03/27/14 - 3.78
Market Cap
516.8M
Average Volume 10 Days
50.5K
EPS TTM
8.27
Shares Outstanding
61.9M
EX-Date
09/24/12
P/E TM
1.0x
Dividend
--
Dividend Yield
--
Current Stock Chart for PARABOLIC DRUGS LTD (PDL)

Related News

No related news articles were found.

parabolic drugs ltd (PDL) Related Businessweek News

No Related Businessweek News Found

parabolic drugs ltd (PDL) Details

Parabolic Drugs Limited develops and manufactures active pharmaceutical ingredients (API) and API intermediates. The company offers oral and sterile semi synthetic penicillin APIs; and oral and sterile cephalosporin APIs in antibiotic area, as well as non-antibiotic APIs for cardiovascular, NSAID, anti-hypertensive, and osteoporosis therapeutic areas. It also provides custom research and manufacturing services to pharma companies, including research and development, and manufacturing services for NCE and generics; IPR support for process design and infringement guidance; and QA, QC, and regulatory support for meeting quality and documentation requirements. The company markets its products in approximately 50 countries, primarily including the Middle East, the United Kingdom, Africa, China, Korea, Japan, the European Union, Latin America, the United States, and ASEAN. Parabolic Drugs Limited was founded in 1996 and is headquartered in Chandigarh, India.

1,011 Employees
Last Reported Date: 07/20/10
Founded in 1996

parabolic drugs ltd (PDL) Top Compensated Officers

Chairman, Managing Director and Member of Aud...
Total Annual Compensation: 12.4M
Whole-Time Director
Total Annual Compensation: 6.3M
Compensation as of Fiscal Year 2014.

parabolic drugs ltd (PDL) Key Developments

Parabolic Drugs Limited Announces Resignation of Balwan Bansal from the Board of Director

Parabolic Drugs Limited has informed that the Board of Director in its Meeting held on February 14, 2015 approved the resignation of Mr. Balwan Bansal from the Board of Director of the Company.

Parabolic Drugs Limited Appoints R.K. Bhalla & Associates as Secretarial Auditor

Parabolic Drugs Limited at the board meeting held on February 14, 2015, appointed R.K. Bhalla & Associates, Practicing Company Secretary as Secretarial Auditor of the company.

Parabolic Drugs Ltd., Board Meeting, Feb 14, 2015

Parabolic Drugs Ltd., Board Meeting, Feb 14, 2015. Agenda: To consider and approve/take on record the unaudited financial results of the company for the quarter ended December 31, 2014; to appoint auditor; and to consider resignation of Mr. Balwan Bansal from the board of directors of the company.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PDL:IN 8.35 INR -0.25

PDL Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PDL.
View Industry Companies
 

Industry Analysis

PDL

Industry Average

Valuation PDL Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book -- Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact PARABOLIC DRUGS LTD, please visit www.parabolicdrugs.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.